CareDx (NASDAQ:CDNA) Announces Earnings Results

CareDx (NASDAQ:CDNA) posted its quarterly earnings results on Thursday. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.45, FiscalAI reports. CareDx had a return on equity of 10.58% and a net margin of 25.86%. The company had revenue of $139.36 million for the quarter, compared to analysts’ expectations of $121.96 million. During the same period in the previous year, the firm earned $0.03 EPS. The firm’s revenue was up 39.3% compared to the same quarter last year.

Here are the key takeaways from CareDx’s conference call:

• Strong financial performance: Q3 revenue rose 39% year over year to $139 million, testing volume increased 51% to 75,900 tests, adjusted EBITDA doubled to $30 million, and the company ended the quarter with $250 million in cash and no debt. Management raised full-year 2026 revenue guidance to $520 million–$530 million and adjusted EBITDA guidance to $90 million–$100 million.
• The transplant franchise delivered 21% year-over-year volume growth, led by continued adoption in kidney and lung, while 21 centers are now live on Epic Aura. Management said it expects roughly half of transplant orders to flow through electronic medical-record integrations by year-end, supporting further workflow adoption.
• NavDx specialty oncology revenue grew 37% year over year on a comparable basis, and CareDx is expanding its commercial team, patient access services, electronic ordering, and billing infrastructure. Management believes NavDx revenue per test can increase from approximately $823 to $1,000 or more over time as evidence and adoption expand.
• CareDx remains on track to launch AlloHeme for AML and MDS recurrence monitoring in Q1 2027 and broaden HistoMap Kidney availability in 2027. However, management indicated that meaningful AlloHeme revenue is likely to emerge in 2029, with coverage potentially materializing in 2028, while NavDx radiation-de-escalation evidence remains based primarily on early phase II studies.

CareDx Trading Up 22.2%

Shares of CDNA opened at $87.41 on Friday. The stock has a market cap of $4.52 billion, a P/E ratio of 36.57 and a beta of 2.38. CareDx has a 12-month low of $14.27 and a 12-month high of $90.87. The company has a 50-day moving average of $59.93 and a two-hundred day moving average of $33.63.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CDNA. William Blair upgraded CareDx to a “hold” rating in a report on Thursday, July 16th. HC Wainwright restated a “neutral” rating and issued a $46.00 price objective on shares of CareDx in a research report on Friday, July 31st. Wall Street Zen cut shares of CareDx from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Canaccord Genuity Group set a $99.00 price objective on shares of CareDx in a report on Friday. Finally, Zacks Research cut CareDx from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. Three research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $64.40.

Insider Activity

In other news, Director George Bickerstaff, III sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $46.28, for a total transaction of $925,600.00. Following the completion of the transaction, the director directly owned 134,061 shares of the company’s stock, valued at approximately $6,204,343.08. This represents a 12.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christine Cournoyer sold 16,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $46.94, for a total transaction of $751,040.00. Following the transaction, the director owned 42,943 shares in the company, valued at $2,015,744.42. This represents a 27.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.40% of the stock is owned by insiders.

CareDx Company Profile

CareDx, Inc is a healthcare diagnostics company focused on improving the care of organ-transplant patients. The company develops and commercializes noninvasive tests and digital tools intended to help physicians assess transplant-organ health, identify potential rejection, and support long-term patient management.

Its offerings include AlloSure donor-derived cell-free DNA tests for monitoring transplant recipients, AlloMap gene-expression testing for heart-transplant patients, and HeartCare, which combines AlloMap and AlloSure results.